Sunday 18 October 2026
Export BJDX’s income statement to Excel — free account
Bluejay Diagnostics, Inc.
BJDX Healthcare Medical Devices
Bluejay Diagnostics, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $249,000.00. In the quarter to June 2026, EPS grew 80.1% and free cash flow grew 20.1%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.75
0.03
−3.85%
Follow BJDX
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (98.89%) | (171.56%) | (117.02%) | (126.19%) |
+8 more TTM periods Free account |
|
| (81.07%) | (126.94%) | (99.42%) | (103.45%) | ||
ROIC |
0.00% | (881.17%) | (536.22%) | (714.15%) | |
Return on Tangible Assets |
(77.83%) | (169.10%) | (116.49%) | (190.40%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(3.00) | (6.75) | (14.47) | (15.37) | |
Free Cash Flow |
(6.24) | (6.65) | (6.50) | (6.05) | |
Capital Expenditures |
(0.33) | (0.19) | (0.45) | — | |
| Other line items | |||||
Cash ROIC |
(32.80%) | (84.52%) | (58.34%) | (89.30%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
— | — | 0.00% | 0.00% | |
Interest Coverage |
— | — | (1,007.67) | (35.43) | |
Operating CF/Net income |
0.81 | 0.94 | 0.88 | 0.88 | |
Depreciation/Fixed assets |
0.11 | 0.11 | 0.11 | 0.11 | |
Capex/Depreciation |
(1.84) | (1.13) | (2.61) | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(2.84) | (6.56) | (13.48) | (15.37) | |
Capex per Share |
(0.16) | (0.19) | (0.99) | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | — |
Columns are period end dates